BLASINGLE-USEVIAL1 Generic Approved
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
BOTOX (onabotulinumtoxina) by AbbVie is acetylcholine release inhibitors [moa]. Approved for acetylcholine release inhibitor [epc]. First approved in 1991.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BOTOX is an acetylcholine release inhibitor delivered via intramuscular injection that works by blocking neuromuscular transmission. It is indicated for multiple therapeutic uses including chronic migraine, cervical dystonia, spasticity, and overactive bladder, as well as cosmetic applications. The product has been a cornerstone therapeutic and aesthetic agent since FDA approval in 1991.
$0.112BPart D
LOE ApproachingProduct is approaching loss of exclusivity with established Part D utilization; brand teams should anticipate transition planning and defensive strategies against generic/biosimilar competition.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Started Jul 2025
8 enrolled
Atopic Dermatitis (AD)
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
Started Feb 2025
132 enrolled
Glabellar Lines
A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants
Started Jan 2025
150 enrolled
Forehead Lines
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
Started Jan 2025
130 enrolled
Facial Contouring
Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids
Started Aug 2024
0Adjuvant Zinc May Increase the Efficacy of Botulinum ToxinZinc Supplementation for Botulinum Toxin Treatment of the ForeheadGlabellar Frown Lines+2 more
Worked on BOTOX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.